N,N-二仲丁基乙酰胺 | 57233-37-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N,N-二仲丁基乙酰胺
• 英文名称: Acetamide, N,N-bis(1-methylpropyl)-
• 英文别名: N,N-di(butan-2-yl)acetamide
• CAS: 57233-37-1
• 化学式: C₁₀H₂₁NO
• 分子量: 171.28
• InChiKey: MCDKWCMKCJAFSZ-UHFFFAOYSA-N

物化性质

• 沸点：
  221.1±8.0 °C(Predicted)
• 密度：
  0.861±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] PROCESS OF PREPARING GLYCOLALDEHYDE<br/>[FR] PROCEDE DE PREPARATION DE GLYCOLALDEHYDE
  申请人：SHELL INT RESEARCH

  公开号：WO2005058788A1

  公开（公告）日：2005-06-30

  The invention provides a process of preparing glycolaldehyde by reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst composition which is based on, a) a source of rhodium, and b) a ligand of general formula R1P-R2(I), wherein R1 is a bivalent radical that together with the phosphorous atom to which it is attached is an optionally substituted 2-phospha-tricyclo[3.3.1.13,7}]-decyl group, wherein from 1 to 5 of the carbon atoms has been replaced by a heteroatom, and wherein R2 is a monovalent radical which is an optionally substituted hydrocarbyl group having from 1 to 40 carbon atoms; a catalyst composition of use in said process; and a process of preparing ethylene glycol from the glycolaldehyde thus prepared.

  该发明提供了一种制备甘醛的方法，通过在催化剂组合物的存在下，将甲醛与氢气和一氧化碳反应，所述催化剂组合物基于a)铑的来源，和b)一般式R1P-R2(I)的配体，其中R1是一个二价基团，与其连接的磷原子一起是一个可选择替代的2-磷杂-三环[3.3.1.13,7}]-癸基团，其中1到5个碳原子已被杂原子取代，而R2是一个单价基团，是一个可选择替代的碳氢基团，含有1到40个碳原子；用于该方法的催化剂组合物；以及从制备的甘醛制备乙二醇的方法。
• 2-Phenyl-2h-pyridazine-3-ones
  申请人：——

  公开号：US20030162662A1

  公开（公告）日：2003-08-28

  The invention relates to 2-phenyl-2H-pyridazin-3-ones of the general formula I 1 in which the variables R 1 , R 2 , X, Y and Z have the following meanings: X is halogen; Y is fluorine or chlorine; Z is oxygen; R 1 is hydrogen or C 1 -C 4 -alkyl; R 2 is chlorine, OR 3 or NR 4 R 5 , in which R 3 , R 4 and R 5 have the meanings indicated in claim 1, Z can also be a group NR 6 if R 2 is a group OR 7 , in which R 6 and R 7 have the meanings indicated in claim 1, and to the agriculturally utilizable salts of compounds of the formula I. The invention furthermore relates to the use of compounds I and their salts as herbicides and/or for the desiccation and/or defoliation of plants, herbicidal compositions and compositions for the desiccation and/or defoliation of plants, which contain the compounds I and/or their salts as active substances, and processes for controlling undesired vegetation (weeds) and for the desiccation and/or defoliation of plants using the compounds I and/or their salts.

  该发明涉及一般式I中的2-苯基-2H-吡啶并三酮，其中变量R1、R2、X、Y和Z具有以下含义：X为卤素；Y为氟或氯；Z为氧；R1为氢或C1-C4-烷基；R2为氯、OR3或NR4R5，其中R3、R4和R5具有权利要求1中所指的含义，如果R2为OR7，则Z也可以是NR6基团，其中R6和R7具有权利要求1中所指的含义，并且该发明还涉及一般式I化合物的农业可利用盐。此外，该发明涉及将化合物I及其盐用作除草剂和/或用于植物脱水和/或落叶，含有化合物I和/或其盐作为活性物质的除草剂组合物和用于植物脱水和/或落叶的组合物，以及利用化合物I和/或其盐控制不受欢迎的植被（杂草）和对植物进行脱水和/或落叶的过程。
• 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME
  申请人：Onco Therapy Science, Inc.

  公开号：US20150005302A1

  公开（公告）日：2015-01-01

  The present invention directs a compound represented by formula (I).

  本发明涉及一种由式(I)所表示的化合物。
• Pyrazolone Derivative
  申请人：Gomi Noriaki

  公开号：US20100324091A1

  公开（公告）日：2010-12-23

  A pyrazolone derivative represented by formula (I) below: wherein R 1 to R 3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

  本发明提供了一种由以下式（I）表示的吡唑酮衍生物：其中，R1至R3与权利要求中定义的相同；或其光学异构体、药学上可接受的盐或其水合物或溶剂化物。根据本发明，这种新型的吡唑酮衍生物具有PAI-1生产抑制活性、组织纤维化抑制活性和纤溶活性，对于预防和/或治疗组织纤维化疾病（肺纤维化、肾脏纤维化等）以及由病理性血栓引起的疾病（缺血性心脏病（心肌梗死和心绞痛）、心房血栓、肺栓塞、深静脉血栓性炎症、弥漫性血管内凝血、缺血性脑疾病（脑梗死、脑出血）和动脉硬化）非常有效。此外，本发明还提供了一种用于预防和/或治疗由纤溶酶原激活剂抑制物-1介导的疾病状况或症状的药物制剂，其包括根据本发明的新型吡唑酮衍生物。
• PYRAZOLONE DERIVATIVE
  申请人：Kowa Company, Ltd.

  公开号：EP2172458A1

  公开（公告）日：2010-04-07

  A pyrazolone derivative represented by formula (I) below: wherein R1 to R3 are the same as defined in claims; or an optical isomer, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof is provided. The novel pyrazolone derivative according to the present invention has a PAI-1 production inhibitory activity, a tissue fibrosis inhibitory activity, and a fibrolytic activity, and is effective for preventing and/or treating tissue fibrotic diseases (lung fibrosis, kidney fibrosis, etc.) and diseases of which a pathological thrombus becomes the cause, such as ischemic cardiac diseases (cardiac infarction and angina pectoris), atrial thrombus, lung embolism, deep thrombophlebitis, disseminated intravascular clotting, ischemic brain diseases (brain infarction, brain hemorrhage), and arterial sclerosis. In addition, a pharmaceutical agent for preventing and/or treating the disease conditions or the symptoms mediated by plasminogen activator inhibitor-1, comprising the novel pyrazolone derivative according to the present invention is also provided.

  下式（I）所代表的吡唑酮衍生物： 其中 R1 至 R3 与权利要求中定义的相同；或其光学异构体、药学上可接受的盐或其水合物或溶液。根据本发明的新型吡唑酮衍生物具有 PAI-1 生成抑制活性、组织纤维化抑制活性和纤维分解活性，可有效预防和/或治疗组织纤维化疾病（肺纤维化、肾纤维化等）和病理血栓形成疾病。例如缺血性心脏病（心肌梗塞和心绞痛）、心房血栓、肺栓塞、深部血栓性静脉炎、弥散性血管内凝血、缺血性脑部疾病（脑梗塞、脑出血）和动脉硬化。此外，还提供了一种用于预防和/或治疗由纤溶酶原激活剂抑制剂-1介导的疾病症状的药剂，其中包含根据本发明的新型吡唑酮衍生物。